Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLELIT-012 first-line KRAS G12C-mutant colorectal cancer study
2024-517232-22-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of calderasib in colorectal adenocarcinoma (2 arms), sponsored by Merck & Co. Primary endpoints: Number of participants experiencing dose-limiting toxicity, Part 1: number of participants who experience an adverse event and 2 more. Planned start Sep 2025; status: authorised.
02
Drugs
calderasib
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on 2024-517232-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517232-22-00.